- InSite Vision has filed an Investigational New Drug application in the USA for ISV-205, its proprietary DuraSite eyedrop formulation of the nonsteroidal anti-inflammatory drug diclofenac. The company says it has also been awarded a US patent covering novel uses of topical NSAIDs in the eye. The first indication sought for ISV-205 will be the prevention of the rise in intraocular pressure induced by steroids given after eye surgery.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze